info@biomedres.us   +1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map Crossmark Policy
ISSN: 2574 -1241

Impact Factor : 0.548

e-Prints

Unifocality as Prognostic Factor for Unilateral Retinoblastoma: Preliminary Results of 32 Eyes Treated with Intra-Arterial Chemotherapy Alone

Research Article

Article Title: Unifocality as Prognostic Factor for Unilateral Retinoblastoma: Preliminary Results of 32 Eyes Treated with Intra-Arterial Chemotherapy Alone

Author: Sonia De Francesco*, Alessandro Di Maggio, Paolo Galluzzi, Sara Leonini, Sandra Bracco, Cristina Menicacci, Matteo Barchitta, Giulio Bagnacci and Theodora Hadjistilianou

Published Date: September 09, 2021

DOI: 10.26717/BJSTR.2021.38.006191

Abstract:

Purpose: To evaluate the role of intra-arterial chemotherapy (IAC) in the management of unilateral, unifocal retinoblastoma (RB) as a single therapy, associated to neither focal nor systemic adjunctive therapies.
Methods: Prospective, single center, interventional case series of 32 consecutive eyes diagnosed with unilateral unifocal RB and treated exclusively with selective ophthalmic intra-arterial chemotherapy, with no adjunctive systemic or focal treatments.
Results: Full regression of the lesion was observed in 30 eyes (93.75%). 2 eyes were enucleated. Ophthalmoscopic remissions type I and III with higher calcific component were achieved. Additionally, neither recurrences nor new tumors appeared during the patient follow-up, which ranged from 10 months to 13 years.
Conclusion: Selective intra-arterial chemotherapy has demonstrated to be highly effective in terms of disease control and anatomical preservation in case of unilateral unifocal disease, without requiring any additional systemic and/or focal therapy.